$3.5M Seed round<\/strong>, led by pi Ventures, with participation from Bluehill Capital, SOSV, and others.<\/p>\n\n\n\nHelex is tackling one of biotech\u2019s toughest challenges: delivering genetic medicines directly to the kidney<\/strong>. Using programmable, non-viral lipid nanoparticles (LNPs), the company can deliver therapeutic cargo precisely where it\u2019s needed, unlocking a new generation of disease-modifying treatments<\/strong> for millions of patients who currently have no effective options.<\/p>\n\n\n\nIts first target: Autosomal Dominant Polycystic Kidney Disease (ADPKD), a genetic disorder affecting 12M people worldwide and often leading to dialysis or transplant. Helex aims to change that with a single-dose, non-viral gene-editing therapy that could halt or even reverse disease progression.
Read their press release in the Financial Times: <\/p>\n","protected":false},"excerpt":{"rendered":"
A new hope for patients with genetic kidney diseases. Helex, an SOSV portfolio company and graduate of the IndieBio startup development program, which is developing a new class of targeted medicines for genetic kidney disorders, announced its $3.5M Seed round, led by pi Ventures, with participation from Bluehill Capital, SOSV, and others. Helex is tackling […]<\/p>\n","protected":false},"author":31,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[2517,2518,2447,2519,2516],"tx_company":[1496],"tx_category":[1153,1070,1069],"tx_trend":[30],"tx_program":[],"posts_type":[17],"class_list":["post-20544","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-genetics","tag-kidney","tag-manufacturing","tag-medicine","tag-theraputics","tx_company-helex-bio","tx_category-biopharma","tx_category-human-health","tx_category-therapeutics","tx_trend-human-health-100","posts_type-press"],"acf":{"founder_names":"","founder_positions":"","founder_companies":"","founder_spotlight_image":"","publisher":"Financial Times","author":"","article_url":"https:\/\/www.businesswire.com\/news\/home\/20251030697943\/en\/Helex-Raises-%243.5-Million-in-Seed-Round-to-Advance-Non-Viral-Gene-Therapies-for-Kidney-Diseases","portal_id":""},"yoast_head":"\n
Helex Raises $3.5M Seed to Advance Non-Viral Gene Therapies for Kidney Diseases - SOSV<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sosv.com\/helex-raises-3-5m-seed-round-to-advance-non-viral-gene-therapies-for-kidney-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Helex Raises $3.5M Seed to Advance Non-Viral Gene Therapies for Kidney Diseases\" \/>\n<meta property=\"og:description\" content=\"A new hope for patients with genetic kidney diseases. Helex, an SOSV portfolio company and graduate of the IndieBio startup development program, which is developing a new class of targeted medicines for genetic kidney disorders, announced its $3.5M Seed round, led by pi Ventures, with participation from Bluehill Capital, SOSV, and others. Helex is tackling […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sosv.com\/helex-raises-3-5m-seed-round-to-advance-non-viral-gene-therapies-for-kidney-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"SOSV\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SOSVvc\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-30T14:13:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-30T14:16:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/sosv.com\/wp-content\/uploads\/2024\/12\/1200x627-social-media-2024.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Kira Colburn\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@sosv\" \/>\n<meta name=\"twitter:site\" content=\"@sosv\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kira Colburn\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/sosv.com\/helex-raises-3-5m-seed-round-to-advance-non-viral-gene-therapies-for-kidney-diseases\/\",\"url\":\"https:\/\/sosv.com\/helex-raises-3-5m-seed-round-to-advance-non-viral-gene-therapies-for-kidney-diseases\/\",\"name\":\"Helex Raises $3.5M Seed to Advance Non-Viral Gene Therapies for Kidney Diseases - SOSV\",\"isPartOf\":{\"@id\":\"https:\/\/sosv.com\/#website\"},\"datePublished\":\"2025-10-30T14:13:36+00:00\",\"dateModified\":\"2025-10-30T14:16:40+00:00\",\"author\":{\"@id\":\"https:\/\/sosv.com\/#\/schema\/person\/7e75a18fb382f9524c11bd5e8920d248\"},\"breadcrumb\":{\"@id\":\"https:\/\/sosv.com\/helex-raises-3-5m-seed-round-to-advance-non-viral-gene-therapies-for-kidney-diseases\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/sosv.com\/helex-raises-3-5m-seed-round-to-advance-non-viral-gene-therapies-for-kidney-diseases\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/sosv.com\/helex-raises-3-5m-seed-round-to-advance-non-viral-gene-therapies-for-kidney-diseases\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/sosv.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Helex Raises $3.5M Seed to Advance Non-Viral Gene Therapies for Kidney Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/sosv.com\/#website\",\"url\":\"https:\/\/sosv.com\/\",\"name\":\"SOSV\",\"description\":\"Deep Tech for Human and Planetary Health\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/sosv.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/sosv.com\/#\/schema\/person\/7e75a18fb382f9524c11bd5e8920d248\",\"name\":\"Kira Colburn\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/sosv.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/sosv.com\/wp-content\/uploads\/2025\/03\/kira-colburn-profile-photo.jpg\",\"contentUrl\":\"https:\/\/sosv.com\/wp-content\/uploads\/2025\/03\/kira-colburn-profile-photo.jpg\",\"caption\":\"Kira Colburn\"},\"url\":\"https:\/\/sosv.com\/author\/kira\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Helex Raises $3.5M Seed to Advance Non-Viral Gene Therapies for Kidney Diseases - SOSV","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sosv.com\/helex-raises-3-5m-seed-round-to-advance-non-viral-gene-therapies-for-kidney-diseases\/","og_locale":"en_US","og_type":"article","og_title":"Helex Raises $3.5M Seed to Advance Non-Viral Gene Therapies for Kidney Diseases","og_description":"A new hope for patients with genetic kidney diseases. Helex, an SOSV portfolio company and graduate of the IndieBio startup development program, which is developing a new class of targeted medicines for genetic kidney disorders, announced its $3.5M Seed round, led by pi Ventures, with participation from Bluehill Capital, SOSV, and others. Helex is tackling […]","og_url":"https:\/\/sosv.com\/helex-raises-3-5m-seed-round-to-advance-non-viral-gene-therapies-for-kidney-diseases\/","og_site_name":"SOSV","article_publisher":"https:\/\/www.facebook.com\/SOSVvc\/","article_published_time":"2025-10-30T14:13:36+00:00","article_modified_time":"2025-10-30T14:16:40+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/sosv.com\/wp-content\/uploads\/2024\/12\/1200x627-social-media-2024.jpg","type":"image\/jpeg"}],"author":"Kira Colburn","twitter_card":"summary_large_image","twitter_creator":"@sosv","twitter_site":"@sosv","twitter_misc":{"Written by":"Kira Colburn","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/sosv.com\/helex-raises-3-5m-seed-round-to-advance-non-viral-gene-therapies-for-kidney-diseases\/","url":"https:\/\/sosv.com\/helex-raises-3-5m-seed-round-to-advance-non-viral-gene-therapies-for-kidney-diseases\/","name":"Helex Raises $3.5M Seed to Advance Non-Viral Gene Therapies for Kidney Diseases - SOSV","isPartOf":{"@id":"https:\/\/sosv.com\/#website"},"datePublished":"2025-10-30T14:13:36+00:00","dateModified":"2025-10-30T14:16:40+00:00","author":{"@id":"https:\/\/sosv.com\/#\/schema\/person\/7e75a18fb382f9524c11bd5e8920d248"},"breadcrumb":{"@id":"https:\/\/sosv.com\/helex-raises-3-5m-seed-round-to-advance-non-viral-gene-therapies-for-kidney-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sosv.com\/helex-raises-3-5m-seed-round-to-advance-non-viral-gene-therapies-for-kidney-diseases\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/sosv.com\/helex-raises-3-5m-seed-round-to-advance-non-viral-gene-therapies-for-kidney-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/sosv.com\/"},{"@type":"ListItem","position":2,"name":"Helex Raises $3.5M Seed to Advance Non-Viral Gene Therapies for Kidney Diseases"}]},{"@type":"WebSite","@id":"https:\/\/sosv.com\/#website","url":"https:\/\/sosv.com\/","name":"SOSV","description":"Deep Tech for Human and Planetary Health","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sosv.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/sosv.com\/#\/schema\/person\/7e75a18fb382f9524c11bd5e8920d248","name":"Kira Colburn","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/sosv.com\/#\/schema\/person\/image\/","url":"https:\/\/sosv.com\/wp-content\/uploads\/2025\/03\/kira-colburn-profile-photo.jpg","contentUrl":"https:\/\/sosv.com\/wp-content\/uploads\/2025\/03\/kira-colburn-profile-photo.jpg","caption":"Kira Colburn"},"url":"https:\/\/sosv.com\/author\/kira\/"}]}},"featured_image_src":null,"featured_image_src_square":null,"author_info":{"display_name":"Kira Colburn","author_link":"https:\/\/sosv.com\/author\/kira\/"},"_links":{"self":[{"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/posts\/20544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/users\/31"}],"replies":[{"embeddable":true,"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/comments?post=20544"}],"version-history":[{"count":0,"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/posts\/20544\/revisions"}],"wp:attachment":[{"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/media?parent=20544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/categories?post=20544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/tags?post=20544"},{"taxonomy":"tx_company","embeddable":true,"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/tx_company?post=20544"},{"taxonomy":"tx_category","embeddable":true,"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/tx_category?post=20544"},{"taxonomy":"tx_trend","embeddable":true,"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/tx_trend?post=20544"},{"taxonomy":"tx_program","embeddable":true,"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/tx_program?post=20544"},{"taxonomy":"posts_type","embeddable":true,"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/posts_type?post=20544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}